Scarica l'app Stockscreener
4.16
3.74%
0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
The Manufacturers Life Insurance Company Buys New Shares in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences stock hits 52-week low at $4.61 - Investing.com
Wedbush Initiates Coverage on Solid Biosciences (NASDAQ:SLDB) - Defense World
Solid Biosciences’ (SLDB) Buy Rating Reiterated at HC Wainwright - Defense World
Solid Biosciences (NASDAQ:SLDB) Upgraded at Wedbush - Defense World
Wedbush Initiates Coverage of Solid Biosciences (SLDB) with Outperform Recommendation - MSN
Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Wedbush - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Coverage Initiated by Analysts at Wedbush - MarketBeat
Solid Biosciences' SWOT analysis: gene therapy stock's potential in DMD treatment - Investing.com
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst - Yahoo Finance
Solid Biosciences (NASDAQ:SLDB) Upgraded at Citizens Jmp - Defense World
Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at JMP Securities - Defense World
HC Wainwright Reiterates Buy Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences initiated with an Outperform at JMP Securities - MSN
Learn to Evaluate (SLDB) using the Charts - Stock Traders Daily
Solid Biosciences (NASDAQ:SLDB) Upgraded to Strong-Buy at Citizens Jmp - MarketBeat
JMP Securities Initiates Coverage of Solid Biosciences (SLDB) with Market Outperform Recommendation - MSN
Solid Biosciences stock a buy, says JMP—proprietary capsid tech adds partnership upside - Investing.com Canada
Solid Biosciences (NASDAQ:SLDB) Now Covered by Analysts at JMP Securities - MarketBeat
Point72 Asset Management L.P. Increases Position in Solid Biosciences Inc. (NASDAQ:SLDB) - MarketBeat
Solid Biosciences secures licenses for cardiac gene therapy By Investing.com - Investing.com Canada
Solid Biosciences CEO Alexander Cumbo sells $62,236 in stock By Investing.com - Investing.com Australia
Solid Biosciences CEO Alexander Cumbo sells $62,236 in stock - Investing.com India
Solid Biosciences executive sells shares worth $25,822 By Investing.com - Investing.com Nigeria
Solid Biosciences secures licenses for cardiac gene therapy - Investing.com India
Solid Biosciences' COO David Howton sells $28,396 in stock By Investing.com - Investing.com Nigeria
Solid Biosciences executive sells shares worth $25,822 - Investing.com
Solid Biosciences' COO David Howton sells $28,396 in stock - Investing.com India
Solid Biosciences Announces Collaboration with Mayo Clinic - GlobeNewswire
Solid Biosciences reports inducement grant under Nasdaq listing rule - Yahoo Finance
Solid Biosciences Lands Major Gene Therapy Deal with Mayo Clinic for Heart Disease Breakthroughs - StockTitan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Analysts Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.14 - MarketBeat
(SLDB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Vestal Point Capital LP Boosts Stake in Solid Biosciences Inc. (NASDAQ:SLDB) - MarketBeat
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Solid Biosciences to Present at Citi and Piper Sandler Healthcare Conferences | SLDB Stock News - StockTitan
Cantor Fitzgerald Brokers Reduce Earnings Estimates for SLDB - MarketBeat
Solid Biosciences Reports Increased Losses Amid R&D Focus - TipRanks
(SLDB) Investment Analysis - Stock Traders Daily
Litecoin Climbs 10% In Rally - Investing.com
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth? - Simply Wall St
Perceptive Advisors LLC's Strategic Acquisition in Solid Bioscie - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Solid Biosciences Inc. - GuruFocus.com
FY2024 Earnings Estimate for SLDB Issued By Chardan Capital - MarketBeat
Solid Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment - Investing.com India
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):